CompletedNot Applicable

CsA vs MMC for Preventing Pterygium Recurrence

Egypt40 participantsStarted 2024-04-01

Plain-language summary

aimed to compare the efficacy and safety of topical cyclosporin A (CsA) versus mitomycin C (MMC) as adjunctive therapies in preventing pterygium recurrence after surgical excision.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged 18 years or older. * Diagnosed with primary pterygium extending at least 1 mm onto the cornea. * No prior history of pterygium surgery in the affected eye. Exclusion Criteria: * History of ocular surface diseases such as dry eye or Sjögren's syndrome. * Active ocular infection. * Known hypersensitivity to CsA or MMC. * Systemic conditions requiring immunosuppressive therapy.

What they're measuring

recurrence rate of pterygium

Timeframe: 6 months after surgery

Trial details

NCT IDNCT06944132

SponsorBenha University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-09-30

View on ClinicalTrials.gov More Pterygium trials